Literature DB >> 18635398

Pluripotent human stem cell lines: what we can learn about cancer initiation.

Tamra E Werbowetski-Ogilvie1, Mickie Bhatia.   

Abstract

Although the cancer stem cell (CSC) hypothesis has become an attractive model to account for tumor recurrence, failure to define a cell of origin has created the need to explore alternative models for cancer initiation and maintenance. Recent studies have linked an embryonic stem cell (ESC)-like gene signature with poorly defined high-grade tumors. Here, we review advances in the ESC field with an emphasis on how human pluripotent stem cells (hPSCs) can be used to define early tumorigenic events, including potential miRNA and epigenetic targets, as well as proto-oncogene and tumor suppressor networks that might facilitate hierarchal transformation. These studies allow for investigation of cancer initiation in a manner that cannot be achieved using primary tumors, where only retrospective evaluation of CSC development is possible. By comparing transformed hPSCs with their normal counterparts, we hope to develop novel cell-specific therapies that selectively target CSCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635398     DOI: 10.1016/j.molmed.2008.06.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  13 in total

1.  CD44v6 dependence of premetastatic niche preparation by exosomes.

Authors:  Thorsten Jung; Donatello Castellana; Pamela Klingbeil; Ines Cuesta Hernández; Mario Vitacolonna; David J Orlicky; Steve R Roffler; Pnina Brodt; Margot Zöller
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

2.  Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16.

Authors:  Gang He; Li Chen; Yin Ye; Yi Xiao; Keding Hua; David Jarjoura; Toru Nakano; Sanford H Barsky; Rulong Shen; Jian-Xin Gao
Journal:  Am J Transl Res       Date:  2010-03-25       Impact factor: 4.060

3.  Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker.

Authors:  James J Liu; Rulong Shen; Li Chen; Yin Ye; Gang He; Keding Hua; David Jarjoura; Toru Nakano; Ganju K Ramesh; Charles L Shapiro; Sanford H Barsky; Jian-Xin Gao
Journal:  Int J Clin Exp Pathol       Date:  2010-03-20

4.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

5.  Pediatric primary central nervous system germ cell tumors of different prognosis groups show characteristic miRNome traits and chromosome copy number variations.

Authors:  Hsei-Wei Wang; Yu-Hsuan Wu; Jui-Yu Hsieh; Muh-Lii Liang; Meng-En Chao; Da-Jung Liu; Ming-Ta Hsu; Tai-Tong Wong
Journal:  BMC Genomics       Date:  2010-02-24       Impact factor: 3.969

6.  Identification of Piwil2-like (PL2L) proteins that promote tumorigenesis.

Authors:  Yin Ye; De-Tao Yin; Li Chen; Quansheng Zhou; Rulong Shen; Gang He; Qingtao Yan; Zhenyu Tong; Andrew C Issekutz; Charles L Shapiro; Sanford H Barsky; Haifan Lin; Jian-Jian Li; Jian-Xin Gao
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

7.  Induction of cancerous stem cells during embryonic stem cell differentiation.

Authors:  Hiroaki Fujimori; Mima Shikanai; Hirobumi Teraoka; Mitsuko Masutani; Ken-ichi Yoshioka
Journal:  J Biol Chem       Date:  2012-09-07       Impact factor: 5.157

Review 8.  DNA hypomethylation in cancer cells.

Authors:  Melanie Ehrlich
Journal:  Epigenomics       Date:  2009-12       Impact factor: 4.778

9.  Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine.

Authors:  Jonghwan Kim; Stuart H Orkin
Journal:  Genome Med       Date:  2011-11-29       Impact factor: 11.117

10.  CD133 antigen expression in ovarian cancer.

Authors:  Gabriella Ferrandina; Enrica Martinelli; Marco Petrillo; Maria Grazia Prisco; Gianfranco Zannoni; Stefano Sioletic; Giovanni Scambia
Journal:  BMC Cancer       Date:  2009-07-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.